Legal & General Group
RLAY icon

Legal & General Group’s Relay Therapeutics RLAY Stock Holding History

Legal & General Group’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.39M Buy
127,676
+45,620
+56% +$662K ﹤0.01% 1904
2026
Q1 		$816K Sell
82,056
-27,152
-25% -$243K ﹤0.01% 2205
2025
Q4 		$924K Sell
109,208
-3,108
-3% -$22.2K ﹤0.01% 2240
2025
Q3 		$586K Hold
112,316
– – ﹤0.01% 2397
2025
Q2 		$389K Sell
112,316
-16,899
-13% -$50.3K ﹤0.01% 2514
2025
Q1 		$339K Buy
129,215
+4,329
+3% +$17K ﹤0.01% 2517
2024
Q4 		$515K Buy
124,886
+1,589
+1% +$8.65K ﹤0.01% 2446
2024
Q3 		$873K Buy
123,297
+35,491
+40% +$265K ﹤0.01% 2283
2024
Q2 		$572K Buy
87,806
+719
+0.8% +$4.91K ﹤0.01% 2373
2024
Q1 		$723K Buy
87,087
+11,288
+15% +$110K ﹤0.01% 2299
2023
Q4 		$835K Hold
75,799
– – ﹤0.01% 2260
2023
Q3 		$637K Sell
75,799
-849
-1% -$9.13K ﹤0.01% 2338
2023
Q2 		$963K Buy
76,648
+1,588
+2% +$19.8K ﹤0.01% 2239
2023
Q1 		$1.24M Buy
75,060
+12,726
+20% +$228K ﹤0.01% 2081
2022
Q4 		$931K Sell
62,334
-883
-1% -$16.9K ﹤0.01% 2169
2022
Q3 		$1.41M Buy
63,217
+2,640
+4% +$57.9K ﹤0.01% 2023
2022
Q2 		$1.01M Buy
60,577
+9,527
+19% +$204K ﹤0.01% 2154
2022
Q1 		$1.53M Buy
51,050
+386
+0.8% +$9.37K ﹤0.01% 2092
2021
Q4 		$1.56M Buy
50,664
+11,121
+28% +$351K ﹤0.01% 2119
2021
Q3 		$1.25M Buy
39,543
+6,322
+19% +$213K ﹤0.01% 2180
2021
Q2 		$1.22M Buy
33,221
+7,393
+29% +$244K ﹤0.01% 2159
2021
Q1 		$893K Buy
25,828
+12,157
+89% +$528K ﹤0.01% 2215
2020
Q4 		$568K Sell
13,671
-23,461
-63% -$1.06M ﹤0.01% 2233
2020
Q3 		$1.58M Buy
+37,132
New +$1.42M ﹤0.01% 1865

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Legal & General Group's RLAY Position: Q2 2026 in Review

Legal & General Group increased its Relay Therapeutics (RLAY) stake by 56% in Q2 2026, buying an estimated $662K and bringing the position to 127,676 shares worth $2.39M. The position accounts for ﹤0.01% of the portfolio, ranked #1904.

Legal & General Group first reported a position in RLAY in Q3 2020 and has held it in 24 quarters since. 258 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Legal & General Group held 127,676 shares of Relay Therapeutics worth $2.39M as of Q2 2026.
  • Legal & General Group bought 45,620 Relay Therapeutics shares in Q2 2026, an estimated $662K.
  • Relay Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #1904 holding.
  • Legal & General Group first reported a position in Relay Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • 258 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.